Correction to: Real-Life Barriers to  Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - March 14, 2023 Category: Dermatology Source Type: research

Treatment of Recurrent Melanoma Following Adjuvant Therapy
AbstractIn the era of effective therapies in melanoma, notably the widespread use of two types of adjuvant treatments: anti-PD-1 immunotherapies and therapies targeting the mitogen-activated protein kinase pathway, for BRAF-mutant patients, an important question arises about how to treat these patients in case of recurrent melanoma following adjuvant therapy. Prospective data are lacking in this area and might be difficult to obtain due to the constant progress being made in the field. Therefore, we reviewed available data suggesting that the initial adjuvant treatment received and the following events provide information ...
Source: American Journal of Clinical Dermatology - March 8, 2023 Category: Dermatology Source Type: research

Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management
AbstractAcne vulgaris is one of the most common skin disorders worldwide. It typically affects skin areas with a high density of sebaceous glands such as the face, upper arms, chest, and/or back. Historically, the majority of research efforts have focused on facial acne vulgaris, even though approximately half of patients with facial lesions demonstrate truncal involvement. Truncal acne vulgaris is challenging to treat and poses a significant psychosocial burden on patients. Despite these characteristics, studies specifically examining truncal acne vulgaris are limited, with treatment guidelines largely derived from facial...
Source: American Journal of Clinical Dermatology - March 1, 2023 Category: Dermatology Source Type: research

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
ConclusionEfficacy of baricitinib for adults with severe AA continuously improved over 52 weeks, indicating that long-term treatment may be necessary to observe maximum clinical benefit. There were no new safety signals.ClinicalTrials RegistrationClinicalTrials.gov NCT03570749 and NCT03899259.Video abstractEfficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata: Week-52 Results from BRAVE-AA1 and BRAVE-AA2 (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - March 1, 2023 Category: Dermatology Source Type: research

Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don ’t Know
AbstractIn chronic spontaneous urticaria (CSU), wheals, angioedema, or both appear spontaneously for>  6 weeks. Current recommended treatment options for urticaria target mast cell mediators such as histamine, or activators, such as autoantibodies. The goal of CSU treatment is to treat the disease until it is gone as effectively and safely as possible. As no cure is available for CSU as of now, the treatment is aimed at continuously suppressing disease activity, with complete control of the disease and a normalization of quality of life. To achieve this, pharmacological treatment should be continued until no longer nee...
Source: American Journal of Clinical Dermatology - February 22, 2023 Category: Dermatology Source Type: research

Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials
ConclusionDupilumab improved AD signs and symptoms in patients aged ≥ 60 years; results were comparable to those in patients aged<  60 years. Safety was consistent with the known dupilumab safety profile.Trial RegistrationClinicalTrials.gov: NCT02277743, NCT02277769, NCT02755649, NCT02260986.Graphical abstractVideo abstractDoes dupilumab benefit adults aged 60 years and older with moderate-to-severe atopic dermatitis?(MP4 20,787 KB) (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - February 20, 2023 Category: Dermatology Source Type: research

Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management
AbstractStasis dermatitis is a chronic inflammatory skin disease of the lower extremities. It typically occurs in older individuals and is the cutaneous manifestation of venous hypertension caused by venous reflux. Such retrograde venous blood flow is the result of incompetent venous valves, valve destruction, or venous obstruction. Stasis dermatitis is eczematous. The associated impairment of venous valves may cause swelling of the legs, leading to serious conditions including venous ulcerations. Diagnosis can be challenging because of its clinical resemblance to other skin conditions and poor clinical recognition by phys...
Source: American Journal of Clinical Dermatology - February 17, 2023 Category: Dermatology Source Type: research

Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009 –2022)
ConclusionSSHis are an effective treatment for advanced BCC disease. Given the high discontinuation rates, management of patient expectations is warranted for compliance and achieving long-term efficacy. It is essential to stay updated with the latest discoveries on the efficacy and safety of SSHis. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - February 16, 2023 Category: Dermatology Source Type: research

Review of Laser Treatments for Post-Inflammatory Hyperpigmentation in Skin of Color
AbstractPost-inflammatory hyperpigmentation is an extremely common disorder of pigmentation in skin of color. It most frequently and severely affects phototypes that are rich in melanin and often has a chronic and unpredictable course. It presents significant treatment challenges and often requires a multi-factorial approach. We review the literature available for the optimal use of laser-based devices in the treatment of post-inflammatory hyperpigmentation, particularly for Fitzpatrick skin phototypes III –VI. For the treatment of post-inflammatory hyperpigmentation in skin of color, lasers remain second line to topical...
Source: American Journal of Clinical Dermatology - February 13, 2023 Category: Dermatology Source Type: research